

Anti-plasmodial effectiveness and Hematological effects of combined extracts of *Toddalia asiatica* and *Carica papaya*, in *Plasmodium berghei* infected mice

Robert Omondi ^{1,*}, Richard Mukabana ¹, Catherine Lukhoba ¹ and Jeremiah Gathirwa ²

¹ Department of Biology, University of Nairobi P.O. Box 30197, Nairobi, Kenya.

² Kenya Medical Research Institute, P. O Box 54840 Nairobi, Kenya.

World Journal of Advanced Research and Reviews, 2024, 22(03), 1429–1436

Publication history: Received on 12 May 2024; revised on 22 June 2024; accepted on 24 June 2024

Article DOI: <https://doi.org/10.30574/wjarr.2024.22.3.1844>

Abstract

Background: Artemisinin-resistant parasites pose a danger to the efficacy of malaria treatment. For a very long time, pharmaceutical companies have relied on plants to provide the prototype molecules required to cure *Plasmodium* infections.

Objective: To evaluate the haematological effects and anti-plasmodial efficacy of combined extracts of *Toddalia asiatica* and *Carica papaya* in mice infected with *Plasmodium berghei*.

Methods: 30 mice were divided into 6 groups of 5 mice each. Each experimental mouse received an intraperitoneal injection of an infected blood containing 1×10^6 red blood cells parasitized by *Plasmodium berghei*, followed by daily administration of the plant extracts. Group 1-3 received 500, 250 and 100 mg/kg of the plant extracts respectively. Group 4 received 500mg/kg of a combination of the two plants extracts. Finally group 5 were give distilled water while group 6 was treated with chloroquine for four consecutive days. For toxicity test the animals received 500mg/kg of the plant extracts combination for 14 consecutive days.

Results: At day three following infection, the data demonstrated a significant ($p < 0.05$) decrease in the percentage of parasite load between the infected treatment groups and the negative control group. This reduction persisted until the experiment's conclusion. The two plant extracts combined showed a reduction in parasites that was nearly identical to that of the positive control group. With the exception of MCH and Hb levels, the combination of study plants did not significantly change any of the mice's haematological indices ($P > 0.05$), suggesting that the combination is a reasonably safe treatment for malaria.

Keywords: *Anti-Plasmodium*; *Toddalia asiatica*; *Carica papaya*; Haematological; *In vivo*

1. Introduction

Malaria, a potentially fatal disease caused by *Plasmodium* parasites, is still a major public health concern in many tropical and sub-tropical regions of the world, especially in the countries of sub-Saharan Africa [1]. African Region continued its long-standing position as the principal carrier of the disease's burden in 2021, accounting for over 95% of all cases and 96% of all fatalities due to malaria [2]. Surprisingly, this disease still poses a serious risk for mortality, with young children particularly at risk especially in Africa [3]. While sub-Saharan Africa has the highest malaria endemicity, it can also be found in a few areas in Southeast Asia [4]. Malaria has a huge financial cost and detrimental consequences on national economy as well; in nations where significant transmission occurs, GDP per person can decline by up to 1.3 percent [5]. In Chad, Ghana, Nigeria, and Uganda, for example, the presence of malaria has a

* Corresponding author: Robert Omondi

detrimental effect on overall national production. Sometimes referred to as the "malaria penalty," the decline in economic growth ranged from 0.41 percent in Ghana to as high as 3.8 percent in Nigeria and 8.9 percent in Chad [6,7]. Based on empirical data, malaria's effects on Kenya pose a serious threat to the country's efforts to reach sustainable development goals and have a negative economic impact. Malaria morbidity and mortality are linked to treatment, control, and prevention expenditures, which create a significant financial burden. However, the emergence of drug resistance and cross-resistance against the majority of antimalarials (including atovaquone, sulfadoxine, pyrimethamine, mefloquine, and more recently, the most effective artemisinin derivatives) as well as the declining efficacy of combinations in clinical practice present a significant challenge to malaria case management at the moment [8–11]. In developing countries, there is an urgent need to discover new therapeutic agents or drug combinations that can battle drug resistance and cure malaria more rapidly and efficiently [12]. Medicinal plants have played a major role in the discovery and development of anti-malarial drugs. And it is expected that medicinal plants will continue to provide new therapeutic leads because of their chemo-diversity [13]. Plant extracts analysis can not only lead to the discovery of novel anti-malarial compounds, but they may also enable researchers to reorient their focus from discovering new, potent chemicals to combining existing chemical agents with plant extracts in an effort to increase medication sensitivity [14,15]. Since plant extracts provide the most cost-effective way to find new anti-malarial drugs [16–18]. The anti-plasmodial efficacy and haematological effects of a combination of extract of *Toddalia asiatica* and *Carica papaya* were assessed in this study using mice infected with *Plasmodium berghei*.

2. Material and methods

2.1. Collection and Extraction of plant material

Toddalia asiatica and *Carica papaya* were collected from Homa-Bay County, Kenya. After being thoroughly washed with distilled water, the collected plant samples were allowed to dry in a shady area until they reached a constant weight. The plant samples were then finely ground using an electric blender. The plant samples were then extracted using polar organic solvents with increasing polarity (methanol, hexane, and ethyl acetate). As shown in Figure 1 below, this was accomplished by immersing 150 g of each sample in 400 mL of the organic solvent for 72 hours. A rotary evaporator was then used to dry the extract filtrate. Before being used, the dried plant extracts were stored at -20°C.




Figure 1 Schematic representation of the extraction procedure of medicinal plants using organic solvent of different polarity

2.2. *Plasmodium berghei* inoculation in mice

Inbred Swiss albino mice weighing around 20 grams were used in this study. The animals were kept in rodent cages and given access to unlimited water and mouse pellets for food. The animals were randomly allocated to four cages and

given a week to adjust to their new surroundings before being infected with *P. berghei*. Five mice were kept in each cage. When the parasitemia of the donor mice peaked (109 parasites/ml), the parasites were extracted from their blood and diluted with regular saline [19]. Every experimental animal received an intraperitoneal injection of 0.2 mL of an infected blood dilution containing 1×10^6 *P. berghei* parasitized red blood cells from donor mice. After a five-day incubation period, blood samples were obtained from the tail vein to assess the infection status of the mice. The plant extract's efficiency against malaria parasites was then assessed on the infected mice.

2.3. *In vivo* assay of single and combined plant extracts

The effectiveness of plant extracts was assessed using the four-day Peters suppressive test method. [19]. On day 0 (the day of infection), two hours after receiving the parasite injection, mice were given an oral dose of a test plant extract. 500 mg/kg of body weight was the starting dosage for the treatment. For four days, the same dosage was given twice a day. On the fifth day, a drop of blood was taken from each mouse's tail to make thin blood smears. After that, the slides were fixed with methanol and stained using a 10% Giemsa solution. Red blood cells (RBCs) infected with parasites were counted under a microscope in ten randomly chosen fields per slide [20]. The parasitaemia percentage was thus calculated as:

$$\% \text{ Parasitemia} = (\text{Number of infected RBCs}) / (\text{Total number RBCs}) \times 100$$

Using the controls as a benchmark, the mean percentage suppression of parasitaemia was calculated.

$$\% \text{ Suppression of Parasitaemia} = (A - b) / A \times 100$$

A is the mean percentage parasitaemia in negative control group. B is the mean percentage parasitaemia in the test group [21,22]. Ethyl acetate and Methanol extracts of *Toddalia asiatica* and *Carica papaya* respective were used for this study.

2.4. Haematological Analysis

An automatic blood cells analyzer (Hemavet 950). was used to count the haemoglobin, hemocrit, red blood cells, and leucocytes in whole blood. The values of the animals' haemoglobin, haematocrit (packed cell volume), and red blood cell count were obtained before calculating their red cell indices. Thus, RBC indices such as mean corpuscular volume (MCV), MCH, and mean corpuscular haemoglobin concentration were calculated using the link between haematocrit, haemoglobin, and red blood cells (MCHC). The haematocrit (Hct) was divided by the RBCs to get the mean corpuscular volume, or MCV. By dividing the total amount of haemoglobin (Hb) by the number of red blood cells (RBCs), the mean haemoglobin content (MCH) was determined. Lastly, by dividing haemoglobin by hemocrit, the mean concentration of haemoglobin per unit volume of red blood cells, or MCHC, was determined [23–25].

2.5. Data analysis

For data analysis, the raw data was first entered into Microsoft Excel and then imported into Minitab 19 software. One-way ANOVA was used to compare the differences in the parasite response to the plant extracts. The two sample t-test of the means was used to analyze the haematological parameters. P-values less than 0.05 were considered statistically significance.

3. Results

Based on the outcomes of the Peters four-day suppressive test, the extracts demonstrated strong anti-plasmodial activity against *P. berghei*, which is susceptible to chloroquine, at the early stages of infection. The best effectiveness of the extract in suppressing parasites was observed at 500 and 250 mg/kg body weight. Though, there was some suppression at 100 kg/body weight. In comparison to the negative control, the extract showed a decrease in the number of parasites at every dose level that was investigated. The study demonstrated the strong activity of *Toddalia asiatica* and *Carica papaya*, as demonstrated by their over 80% suppression at all dosages. *Carica papaya* and *Toddalia asiatica* achieved a percentage suppression range (>90%) at the maximum dose of the extract (500 mg/kg), which is noteworthy because it is similar to the dose of chloroquine used as a reference medication. In general, the two test plants each demonstrated a parasite suppression rate of more than 70% at 250 mg/kg body weight when administered individually to treat the malaria in mice. However, as indicated in Table 1, when the combination of the two plants extracts was assessed *in vivo* for its capacity to decrease parasite density on the fourth day, it revealed that the combination of *Carica papaya* and *Toddalia asiatica* extracts at a ratio 1:1 (250mg/kg *Carica* + 250 mg/kg *Toddalia*) had an over 90% suppression rate of *Plasmodium berghei* in mice. This indicated that higher effects witnessed by administering higher

dosage (500mg/kg) of the plant extract, can easily be achieved by administering a smaller dose (250mg/kg) of the two plant extracts in combinations.

Table 1 Plant extracts' effects on mice's early infection with malaria parasite

| Extract | Dose mg/kg | PRBC | RBC | % Parasitemia | Suppression |
|-------------------------|------------|-------|--------|---------------|-------------|
| Carica | 500 | 2.08 | 565.15 | 0.3651 | 95% |
| | 250 | 7.55 | 643.05 | 1.1757 | 84.43% |
| | 100 | 6.80 | 504.1 | 1.4728 | 80.36% |
| Toddalia | 500 | 1.31 | 782.85 | 0.1779 | 98% |
| | 250 | 7.4 | 537.80 | 1.4155 | 81% |
| | 100 | 7.7 | 584.57 | 1.4656 | 80% |
| C. papaya + T. asiatica | 100+100 | 6.0 | 584.57 | 1.2850 | 82% |
| | 250+250 | 3.60 | 586.47 | 0.6275 | 91.7% |
| NC (Water) | 1 ml | 32.83 | 456.08 | 7.5409 | N/A |
| CQ | 10MG | 0.39 | 465.78 | 0.0861 | 99% |

3.1. Effects of *Toddalia asiatica* extracts on haematological parameter of mice

RBC count, total RBC indices, and HB estimate can provide an accurate indication of the plant extract's possible negative effects on an animal's hemopoietic activities after it has been administered. The changes in the mice's haematological parameters after a 14-day treatment with *Toddalia* are shown in Table 2. Extracts of *Toddalia* had no significant effect on any of the mouse haematological parameters (Hb, haemoglobin, MCV, MCH, MCHC, leucocytes, and platelets; $P > 0.05$), with the exception of RBC counts, which were significantly ($P = 0.014$) lower in the groups that received the extract at a dose of 500 mg/kg than in the control group.

Table 1 Haematological values of mice after treatment with *Toddalia asiatica*

| Variable | Animal group | Mean | SE Mean | StDev | p- value |
|-----------------|--------------|--------|---------|-------|----------|
| Hb Hb (g/dL) | Control | 12.833 | 0.401 | 0.983 | 0.781 |
| | Treatment | 12.667 | 0.422 | 1.033 | |
| Haematocrit (%) | Control | 41.33 | 2.29 | 5.61 | 0.400 |
| | Treatment | 44.00 | 1.97 | 4.82 | |
| RBC (x106/mm3) | Control | 8.833 | 0.477 | 1.169 | 0.014 |
| | Treatment | 7.000 | 0.365 | 0.894 | |
| MCV (fl) | Control | 50.50 | 1.57 | 3.83 | 0.350 |
| | Treatment | 48.33 | 1.54 | 3.78 | |
| MCH (pg) | Control | 16.000 | 0.775 | 1.897 | 0.404 |
| | Treatment | 15.167 | 0.543 | 1.329 | |
| MCHC (%) | Control | 30.333 | 0.715 | 1.751 | 0.176 |
| | Treatment | 31.667 | 0.558 | 1.366 | |
| WBC (X 103/mm3) | Control | 3.333 | 0.615 | 1.506 | 0.075 |
| | Treatment | 1.833 | 0.401 | 0.983 | |

| | | | | | |
|-----------------------|-----------|-------|------|-------|-------|
| Platelets (X 103/mm3) | Control | 579.8 | 34.6 | 84.8 | 0.130 |
| | Treatment | 683.0 | 50.4 | 123.4 | |

3.2. Effects of *Carica papaya* extracts on haematological parameters of mice

As indicated in Table 3, following a 14-day administration of *C. papaya* extracts. There was a significant ($P < 0.05$) difference in the mean RBC count and Hb levels between the experimental and control groups after receiving *Carica papaya* extracts. Nevertheless, there was no significant difference in mean leucocyte and platelet counts between the experiment and control groups ($P > 0.05$). Mice given *Carica papaya* extracts did not also show a significant ($P > 0.05$) change in MCV, MCH, or MCHC levels, according to the study.

Table 3 Haematological values in mice after treatment with *Carica papaya* extract

| Variable | Animal group | Mean | SE Mean | StDev | P-value |
|-----------------------|--------------|--------|---------|-------|---------|
| Hb (g/dL) | Control | 12.833 | 0.401 | 0.983 | 0.032 |
| | Treatment | 11.500 | 0.342 | 0.837 | |
| Haematocrit (%) | Control | 41.33 | 2.29 | 5.61 | 0.306 |
| | Treatment | 37.83 | 2.27 | 5.56 | |
| RBC (x106/mm3) | Control | 8.833 | 0.477 | 1.169 | 0.049 |
| | Treatment | 7.500 | 0.342 | 0.837 | |
| MCV (fl) | Control | 50.50 | 1.57 | 3.83 | 0.65 |
| | Treatment | 46.67 | 1.99 | 4.89 | |
| MCH (pg) | Control | 16.000 | 0.775 | 1.897 | 0.489 |
| | Treatment | 16.667 | 0.494 | 1.211 | |
| MCHC (%) | Control | 30.333 | 0.715 | 1.751 | 0.176 |
| | Treatment | 31.667 | 0.558 | 1.366 | |
| WBC (X 103/mm3) | Control | 3.333 | 0.615 | 1.506 | 0.667 |
| | Treatment | 3.667 | 0.422 | 1.033 | |
| Platelets (X 103/mm3) | Control | 579.8 | 34.6 | 84.8 | 0.614 |
| | Treatment | 624.7 | 76.8 | 188.1 | |

3.3. Effects of Combined *Carica papaya* and *Toddalia asiatica* on haematological parameters of mice

All of the mouse haematological parameters (Hb, haemoglobin, MCV, MCH, MCHC, leucocytes, and platelets) were not significantly affected ($P > 0.05$), by extracts of *Toddalia asiatica* and *Carica papaya* when administered in combination (Table 4). However, MCH and Hb were significantly ($P < 0.05$) lower in the groups that received the extract at a dose of 500 mg/kg than in the control group.

Table 2 Haematological parameters in mice treated with *Toddalia asiatica* and *Carica papaya* in combination

| Variable | Animal group | Mean | StDev | SE Mean | P-VALUE |
|-----------------|--------------|-------|-------|---------|---------|
| Hb (g/dL) | control | 10.83 | 1.47 | 0.6 | 0.028 |
| | treatment | 12.83 | 1.17 | 0.48 | |
| Haematocrit (%) | control | 45.83 | 2.64 | 1.1 | 0.085 |

| | | | | | |
|-----------------------|-----------|-------|-------|------|-------|
| | Treatment | 40.17 | 6.21 | 2.5 | |
| RBC (x106/mm3) | Control | 8.333 | 0.816 | 0.33 | 0.517 |
| | Treatment | 8 | 0.894 | 0.37 | |
| MCV (fl) | Control | 43.67 | 1.86 | 0.76 | 0.279 |
| | Treatment | 46.17 | 4.79 | 2 | |
| MCH (pg) | Control | 13.67 | 1.03 | 0.42 | 0.019 |
| | Treatment | 15.67 | 1.37 | 0.56 | |
| MCHC (%) | Control | 30.33 | 1.21 | 0.49 | 0.665 |
| | Treatment | 30.67 | 1.37 | 0.56 | |
| WBC (X 103/mm3) | Control | 3.833 | 0.983 | 0.4 | 0.298 |
| | Treatment | 3 | 1.55 | 0.63 | |
| Platelets (X 103/mm3) | Control | 648 | 137 | 56 | 0.228 |
| | Treatment | 562.5 | 84.1 | 34 | |

4. Discussion

The results of the four-day suppressive test showed that the extract exhibited strong anti-plasmodial activity against chloroquine-sensitive *P. berghei* on early infection. The highest levels of extract suppression of parasites were observed at 500 and 250 mg/kg body weight. There was also some suppression at 100 kg/body weight (Table 1). At every studied dose level, the extract exhibited a dose-dependent, statistically significant ($p < 0.05$) reduction in parasite count as compared to the negative control. The combination of two or more plant extracts can have antagonistic or synergistic effects on *Plasmodium berghei* in mice. When the combination of ingredients improves each other's performance, they are said to have a synergistic effect [26]. When the two test plants were administered separately to treat the malaria parasite in mice, each had a parasite suppression rate of about 70% at 250 mg/kg body weight dosage. On the other hand, mice given extracts of *Carica papaya* and *Toddalia asiatic* combine at a ratio of 1:1 demonstrated at least an 80% reduction in *Plasmodium berghei*, which was equivalent to that of the positive control (chloroquine test group). This means that you can combine low doses of plant extracts to obtain the same therapeutic benefits and potency as higher dosages (500 mg/kg), which are usually associated with toxic symptoms. Similar research on the combined synergistic anti-plasmodial activity of plant extracts showed that there was no discernible synergistic toxicity associated with the plant extracts' synergistic anti-malarial effects on parasites [27]. Combinations of drugs improve the effectiveness of each one and enable dosage reductions. It is possible to prevent concentration-related toxicity by lowering the dosage of the combination drugs. Reducing toxicity (by lowering drug doses) and increasing efficacy (via drug interactions) are the primary objectives of employing pharmacological combinations in therapeutic settings. Results from this investigation showed that, rather than using a larger single dosage of 500 mg/kg, 250 mg/kg extracts of the two study plants should be combined in a 1:1 ratio to provide the best anti-plasmodial effects *in vivo*. This may reduce the harmful effects linked to larger dosages during chemotherapy. This is in line with other research that shown the plant's ability to inhibit the malaria parasite in mice was much enhanced when extracts from several plants were combined in a 1:1 ratio [26].

Following a 14-day period of 500 mg/kg plant extract administration to mice, changes in their haematological parameters were evaluated. The study's findings demonstrated that the leaf extract of *Toddalia* had no discernible effect on the haematological parameters in mice (Hb, haemoglobin, MCV, MCH, MCHC, leucocytes, and platelets) ($P > 0.05$). According to earlier studies, *T. asiatica* has a significant amount of easily obtainable iron that can be used to support the production of blood. The plant's copper facilitates the transformation of iron (II) into iron (III), which is needed to produce erythrocytes [28]. This may have offset any negative changes in blood parameters resulting from the toxicity of the herbal extract to red blood cells in this investigation. Giving mice *Carica papaya* extracts also had no discernible ($P > 0.05$) effects on the mice's MCV, MCH, MCHC, or RBC count. This is consistent with other research showing that *Carica papaya* can raise haemoglobin and erythrocyte counts [29]. It has been shown in earlier studies that oral administration of *C. papaya* leaf extract has a statistically significant effect on platelet counts. Furthermore, compared to the control group of animals, the test group's RBC count increased considerably [30]. A dengue patient in Pakistan showed improvement in platelet count after receiving aqueous extract of *C. papaya* leaves (25 mL, twice daily for five

consecutive days). This supports the use of the plant extract as a blood booster in herbal medicine practices [31]. When administered together in ratio of 1:1, extracts of *Toddalia* and *Carica papaya* did not substantially alter any of the mice haematological indices (Hb, haemoglobin, MCV, MCH, MCHC, leucocytes, and platelets; $P > 0.05$). However, the groups that were administered 500 mg/kg of the extract combination had considerably ($P < 0.05$) lower levels of MCH and Hb compared to the control group. This is likely owing to the lowered hemopoietic activities caused by the co-administration of the plant extracts.

5. Conclusion

When the three test plants were administered separately to treat the malaria parasite in mice, each had a parasite suppression rate of more than 70% at 250 mg/kg body weight. On the other hand, mice given a 1:1 ratio of 250 mg/kg of *Carica papaya* and *Toddalia asiatic* combined extracts had at least an 80% reduction in *Plasmodium berghei*, which was almost equivalent to that of the positive control. This means that you can use a mixture of low dosages of plant extracts to obtain the same therapeutic benefits and potency as larger dosages (500 mg/kg), which are typically linked to toxic symptoms. With the exception of MCH and Hb levels, the combination of study plants did not significantly change any of the mice's haematological indices (Hb, haemoglobin, MCV, MCH, MCHC, leucocytes, and platelets; $P > 0.05$), suggesting that the combination is a reasonably safe treatment for malaria.

Compliance with ethical standards

Acknowledgements

The authors are thankful to Miss Diana Atieno of Kenya Medical Research Institute for her contribution during this study.

Disclosure of Conflict of interest

No conflict of interest to be disclosed.

References

- [1] WHO. Fact sheet about malaria. 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/malaria>
- [2] WHO Report. World malaria report 2021. WHO. 2021. Available from: <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021>
- [3] Kokori E, Olatunji G, Akinboade A, Akinoso A, Egbunu E, Aremu SA, *et al.* Triple artemisinin - based combination therapy (TACT): advancing malaria control and eradication efforts. *Malar J* . 2024;1–7.
- [4] Organization WHO. World malaria report 2022. World Health Organization; 2022. Available from: <https://books.google.co.ke/books?id=ST-hEAAAQBAJ>
- [5] Andrade M V., Noronha K, Diniz BPC, Guedes G, Carvalho LR, Silva VA, *et al.* The economic burden of malaria: a systematic review. *Malar J* . 2022;21:1–10.
- [6] Okorosobo T, Mwabu G, Nabyonga Orem J, Kirigia J. Economic Burden of Malaria in six Countries of Africa. *J. Bus. Mark. Manag.* 2011.
- [7] Elnour Z, Grethe H, Siddig K, Munga S. Malaria control and elimination in Kenya: economy-wide benefits and regional disparities. *Malar J* . 2023;22:117.
- [8] Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, *et al.* Spread of Artemisinin Resistance in *Plasmodium falciparum* Malaria. *N Engl J Med* . 2014;371:411–23.
- [9] Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, *et al.* Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. *N Engl J Med*. 2023;389:722–32.
- [10] Nsanjabana C. Resistance to artemisinin combination therapies (ACTs): Do not forget the partner Drug! *Trop Med Infect Dis*. 2019;4.
- [11] Capela R, Moreira R, Lopes F. An overview of drug resistance in protozoal diseases. *Int J Mol Sci*. 2019;20.

- [12] Pandey SK, Anand U, Siddiqui WA, Tripathi R. Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery—An Update. *Adv Med.* 2023;2023:1–10.
- [13] Irungu B, Okari E, Nyangi M, Njeru S, Koech L. Potential of medicinal plants as antimalarial agents: a review of work done at Kenya Medical Research Institute. *Front Pharmacol.* 2023;14.
- [14] Kong D-X, Li X-J, Zhang H-Y. Where is the hope for drug discovery? Let history tell the future. *Drug Discov Today.* 2009 ;14:115–9.
- [15] Wagner H, Ulrich-Merzenich G. Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine.* 2009;16:97–110.
- [16] Wilcox M, Chamberlain J. No Title. In: Willcox M, Bodeker G, Rasoanaivo CRC, editors. *Neem (Azadirachta indica) Tradit Med Plants Malar.* 2004.
- [17] Elujoba A. THE ROLE OF PHARMACOGNOSY IN PHYTOTHERAPY — THE CHALLENGES OF OUR TIME. *Niger J Nat Prod Med .* 1998;2:5–8.
- [18] Koffi JA, Silué KD, Tano DK, Dable TM, Yavo W. Evaluation of antiplasmodial activity of extracts from endemic medicinal plants used to treat malaria in Côte d'Ivoire. *Bioimpacts.* 2020;10:151–7.
- [19] PETERS, J. W. The chemotherapy of rodent malaria XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizonticidal activity. *Ann Trop Med Parasitol.* 1975;69:155–71.
- [20] Adetutu A, Olorunnisola OS, Owoade AO, Adegbola P. Inhibition of In Vivo Growth of *Plasmodium berghei* by *Launaea taraxacifolia* and *Amaranthus viridis* in Mice. Valecha N, editor. *Malar Res Treat.* 2016;2016:9248024.
- [21] Ettebong EO, Nwafor PA, Okokon JE. In vivo antiplasmodial activities of ethanolic extract and fractions of *Eleusine indica*. *Asian Pac J Trop Med.* 2012;5:673–6.
- [22] Ryley JF, Peters W. The antimalarial activity of some quinolone esters. *Ann Trop Med Parasitol .* 1970;64.
- [23] Baker JF, Silvertown ER KD. Introduction to Medical Laboratory Technology. *Ann. Intern. Med.* 1983.
- [24] Barve S, Patel D, K K S, Jawarkar A. Role of Rbc Count and Rbc Indices in Diagnosing and Differentiating Anemias Caused Due To Various Clinical Situations in a Tertiary Care Hospital in Vadodara, Gujarat. *J Evid Based Med Healthc.* 2015;2:8146–8.
- [25] Naeim F, Nagesh Rao P, Song SX, Grody WW. 61 - Disorders of Red Blood Cells—Anemias. In: Naeim F, Nagesh Rao P, Song SX, Grody WWBT-A of H, editors. *Academic Press;* 2013. p. 675–704.
- [26] Rosmalena F, Amalia A, Syafitri I, Prasasty VD. Antimalarial Effect of Flamboyant (*Delonix regia*) Bark and Papaya (*Carica papaya* L) Leaf Ethanolic Extracts against *Plasmodium berghei* in Mice. *Biomed Pharmacol J.* 2017;10:1081–9.
- [27] Azas N, Laurencin N, Delmas F, Di Giorgio C, Gasquet M, Laget M, *et al.* Synergistic in vitro antimalarial activity of plant extracts used as traditional herbal remedies in Mali. *Parasitol Res.* 2002;88:165–71.
- [28] Mogwasi R. Bio-accessibility of iron and copper from seven Kenyan anti-anaemia medicinal plants. *Diagnostics Ther.* 2022;2:1–12.
- [29] Hamidah A, Anggereini E, Nurjanah N. Effect of *Carica papaya* Leaf Juice on Hematology of Mice (*Mus musculus*) with Anemia. *Biosaintifika J Biol Biol Educ.* 2017;9:417.
- [30] Dharmarathna SLCA, Wickramasinghe S, Waduge RN, Rajapakse RPVJ, Kularatne SAM. Does *Carica papaya* leaf-extract increase the platelet count? An experimental study in a murine model. *Asian Pac J Trop Biomed.* 2013;3:720–4.
- [31] Afzan A, Abdullah NR, Halim SZ, Rashid BA, Semail RHR, Abdullah N, *et al.* Repeated dose 28-days oral toxicity study of *Carica papaya* L. Leaf extract in Sprague Dawley rats. *Molecules.* 2012;17:4326–42.